Novel Cancer Drug Shows Promise for Mesothelioma Patients in Clinical Trial
A new targeted therapy for solid tumors shows particular promise for mesothelioma patients with limited treatment options. The YAP/TEAD inhibitor demonstrated a 32% response rate in optimized dosing groups with manageable safety profile.
Breakthrough Targeted Therapy Shows Promise for Rare Cancers
A novel cancer drug targeting the Hippo signaling pathway has demonstrated encouraging results for patients with advanced mesothelioma and other solid tumors, according to a recent report published in Nature Medicine. The phase 1/2 clinical trial of VT3989, a YAP/TEAD inhibitor, showed significant antitumor activity particularly in mesothelioma patients who had exhausted standard treatment options.